Acumen Pharmaceuticals宣布提名两款增强型脑部递送™ (EbD™) 开发候选药物用于治疗阿尔茨海默病

美股速递06-16 19:31

Acumen Pharmaceuticals, Inc. 宣布，已提名两款基于其增强型脑部递送™ (EbD™) 技术平台的开发候选药物，用于治疗阿尔茨海默病。此举标志着该公司在攻克这一神经退行性疾病领域的研发管线取得了重要进展。

这两款候选药物的提名，旨在利用其专有的EbD™技术，更有效地将治疗性分子递送至大脑靶点，以期改善阿尔茨海默病患者的治疗效果。公司计划推进相关临床前及后续的临床开发工作。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1130256716?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-16 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130256716","market":"us","top_or_hot":-1,"title":"Acumen Pharmaceuticals宣布提名两款增强型脑部递送™ (EbD™) 开发候选药物用于治疗阿尔茨海默病","media":"美股速递","content":"<p>Acumen Pharmaceuticals, Inc. 宣布，已提名两款基于其增强型脑部递送™ (EbD™) 技术平台的开发候选药物，用于治疗阿尔茨海默病。此举标志着该公司在攻克这一神经退行性疾病领域的研发管线取得了重要进展。</p>\n<p>这两款候选药物的提名，旨在利用其专有的EbD™技术，更有效地将治疗性分子递送至大脑靶点，以期改善阿尔茨海默病患者的治疗效果。公司计划推进相关临床前及后续的临床开发工作。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen Pharmaceuticals宣布提名两款增强型脑部递送™ (EbD™) 开发候选药物用于治疗阿尔茨海默病</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen Pharmaceuticals宣布提名两款增强型脑部递送™ (EbD™) 开发候选药物用于治疗阿尔茨海默病\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-16 19:31 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Acumen Pharmaceuticals, Inc. 宣布，已提名两款基于其增强型脑部递送™ (EbD™) 技术平台的开发候选药物，用于治疗阿尔茨海默病。此举标志着该公司在攻克这一神经退行性疾病领域的研发管线取得了重要进展。\n这两款候选药物的提名，旨在利用其专有的EbD™技术，更有效地将治疗性分子递送至大脑靶点，以期改善阿尔茨海默病患者的治疗效果。公司计划推进相关临床前及后续的临床开发工作。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABOS","symbol_name":"Acumen Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1130256716","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130256716","pubTimestamp":1781609510,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Acumen Pharmaceuticals, Inc. 宣布，已提名两款基于其增强型脑部递送™ (EbD™) 技术平台的开发候选药物，用于治疗阿尔茨海默病。此举标志着该公司在攻克这一神经退行性疾病领域的研发管线取得了重要进展。\n这两款候选药物的提名，旨在利用其专有的EbD™技术，更有效地将治疗性分子递送至大脑靶点，以期改善阿尔茨海默病患者的治疗效果。公司计划推进相关临床前及后续的临床开发工作。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ABOS":"Acumen Pharmaceuticals, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Acumen Pharmaceuticals Announces Nominations for Two Enhanced Brain Delivery ™ (EbD ™ ) Development of drug candidates for the treatment of Alzheimer's disease","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABOS":1},"content_text":"Acumen Pharmaceuticals, Inc. 宣布，已提名两款基于其增强型脑部递送™ (EbD™) 技术平台的开发候选药物，用于治疗阿尔茨海默病。此举标志着该公司在攻克这一神经退行性疾病领域的研发管线取得了重要进展。\n这两款候选药物的提名，旨在利用其专有的EbD™技术，更有效地将治疗性分子递送至大脑靶点，以期改善阿尔茨海默病患者的治疗效果。公司计划推进相关临床前及后续的临床开发工作。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130256716","isCrawlerRequest":true}